Breast cancer: PET imaging of estrogen receptors.

Mintun, Mark A.; Welch, M. J.; Siegel, Barry A.; Mathias, Carla J.; Brodack, James W.; McGuire, Andrea H.; Katzenellenbogen, John A.

doi:10.1148/radiology.169.1.3262228

Cited by 382 publications

(195 citation statements)

References 0 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…The brain, ovaries, adrenals and skin are less frequently involved. Several other prognostic indicators have been recognized beyond nodal extension: primarily the size of the tumour, the presence or absence of local inflammatory signs, the presence or absence of hormonal receptors [235][236][237] (progesterone receptors have greater prognostic value than oestrogen receptors) and the age of the patient (women under 35 years have twice the rate of axillary involvement as older women). The histopathological classification based on the degree of differentiation (SBR grades I-III) also carries prognostic information [238], as do more recently developed oncogene-related markers [239].…”

Section: Breast Cancermentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

Section: Breast Cancermentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

show abstract

“…The development of estrogen derivatives for the diagnosis and treatment of breast cancer has been of interest for many years [1][2][3], and agents for imaging estrogen receptors (ERs) in breast tumors have also been investigated as a means for obtaining-non-invasively-information on the hormonal sensitivity of the cancer and the likelihood that it can be treated successfully by endocrine therapies [4][5][6]. A number of estradiol derivatives labeled with bromine [7,8], iodine [9], and fluorine [10][11][12] have been developed as tumor imaging agents for this purpose.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor

Seo

Yoon

Dence

et al. 2007

Nuclear Medicine and Biology

View full text Add to dashboard Cite

([ 18 F]FECF, 9), two high affinity non-steroidal estrogens, were prepared and investigated as potential agents for imaging estrogen receptors (ERs) in breast tumors. Both of these compounds could be prepared conveniently from alkyl methanesulfonate precursors (5, 8) by fluoride displacement reactions, and they were obtained in high radiochemical purity and radiochemical yields, with effective specific activities sufficient for in vivo biodistribution studies. While the biodistribution of [ 18 F]6 in immature female rats showed no selective target tissue uptake, the biodistribution of [ 18 F]9 showed selective uptake by the uterus, but this uptake could not be blocked by excess estradiol. The poor in vivo biodistribution of these otherwise high affinity ligands is curious, and together with recent results on the biodistribution of other non-steroidal ligands, it suggests that factors other than receptor binding affinity are important for in vivo imaging of estrogen target tissues and ER-positive breast tumors.

show abstract

“…This radio-labeled ligand of the estrogen receptors (ER) was investigated since 1988 [16,17] and has been successful in the evaluation of hormone receptor status in breast carcinomas [18][19][20]. Further researches focused on the optimization of the imaging with FES PET by analyzing the blood clearance and its interactions with sex hormone binding globulins (SHBGs) [21,22].…”

Section: -α-[mentioning

confidence: 99%

PET-CT Imaging in Breast Cancer Patients: New Tracers, Future Directions

TÅkés¹

2013

J Mol Imag Dynamic

View full text Add to dashboard Cite

Positron Emission Tomography using 18 F-fluoro-deoxi-glucose (FDG-PET) is giving a new perspective in disease staging and therapeutic response evaluation in daily oncological practice. To understand better the biological behavior and therapeutic response of breast cancer, new tracers and targets of molecular imaging are under investigation. These tracers may lead to non-invasive evaluation of the main, leading therapeutic decision-maker properties of metastatic breast cancer such as receptor status, proliferation activity and therapy resistance, and could also become predictive markers in the early measurement of therapeutic response in the neoadjuvant treatment of locally advanced breast cancer. However, these new agents are currently not available in the daily practice; the preliminary results are promising.

show abstract

Breast cancer: PET imaging of estrogen receptors.

Cited by 382 publications

References 0 publications

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor

PET-CT Imaging in Breast Cancer Patients: New Tracers, Future Directions

Contact Info

Product

Resources

About